Paul Chaplin, Bavarian Nordic CEO

Bavar­i­an Nordic inks an­oth­er ma­jor vac­cine con­tract with Cana­da

As mon­key­pox cas­es con­tin­ue to af­fect na­tions in North Amer­i­ca and across the globe, Cana­da is look­ing to step up its pre­ven­tion ef­forts via a boost­ed con­tract with Bavar­i­an Nordic.

The Pub­lic Health Agency of Cana­da (PHAC) an­nounced on Tues­day that it has changed its con­tract with the Dan­ish drug­mak­er. The agree­ment will see Bavar­i­an Nordic de­liv­er its Jyn­neos vac­cine, al­so known as Im­va­mune, to the PHAC at a val­ue of $234 mil­lion, in ad­di­tion to $180 mil­lion in con­tract op­tions span­ning 10 years.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.